Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Rekovelle Market Growth From $ Billion In 2026 To $ Billion By 2030 At A CAGR Of %
The expansion observed during the historic period was driven by several key factors, including rising infertility rates, the proliferation of assisted reproductive technology clinics, and a growing trend toward later maternal age. Additionally, greater access to fertility medications and the clinical endorsement of recombinant hormone therapies played significant roles in this growth.
The expansion during the forecast period is driven by a rising need for IVF treatments, a growing inclination toward customized fertility care, the spread of fertility tourism, greater funding being channeled into reproductive health services, and ongoing breakthroughs in hormonal stimulation therapies. Key developments shaping the forecast period encompass a higher uptake of tailored fertility solutions, increased utilization of recombinant gonadotropins, a stronger emphasis on individualized ovarian stimulation plans, growth in the number of IVF procedures performed globally, and improved accuracy in hormone dosage administration.
Download A Free Sample Report For Comprehensive Market Insights:
Rekovelle Market Growth Drivers And Industry Catalysts
The growing occurrence of infertility worldwide is projected to drive expansion in the rekovelle market in the coming years. Infertility rates describe the percentage of couples or individuals within a defined population who fail to conceive after a year of regular, unprotected sexual activity. This rise in infertility is influenced by factors like postponing childbearing, shifts in lifestyle, exposure to environmental pollutants, and various medical issues, all of which boost demand for fertility solutions. Rekovelle works to lower infertility rates by enhancing ovarian response and improving outcomes of assisted reproductive methods such as IVF, thereby raising the likelihood of successful conception and pregnancy. For example, as reported by the World Health Organization, an intergovernmental entity based in Switzerland, in April 2023, around 17.5% of the global adult population—roughly 1 in 6 individuals—experiences infertility. Consequently, the uptick in infertility prevalence fuels growth within the rekovelle market.
The escalating frequency of genetic disorders is anticipated to accelerate growth of the Rekovelle market moving ahead. Genetic disorders refer to conditions caused by DNA abnormalities, including mutations, deletions, or duplications. The increase in such conditions stems from advanced parental age, which heightens the likelihood of DNA mutations in eggs and sperm. Rekovelle aids patients facing fertility problems tied to genetics by stimulating ovarian follicle development for effective IVF procedures. For instance, according to Gene People, a registered charity in the United Kingdom, as of March 2024, genetic conditions impact an estimated 1 in 25 children, affecting over 2.4 million children and adults across the UK. Hence, the rising prevalence of genetic conditions is fueling expansion of the Rekovelle market.
Rekovelle Market Segment Analysis: What Are The Major Market Categories?
The rekovelle market covered in this report is segmented –
1) By Indication: Controlled Ovarian Stimulation, Polycystic Ovary Syndrome
2) By Distribution Channel: Hospitals, Clinics, Pharmacies
3) By End User: Pediatric, Adult, Geriatric
Rekovelle Market Trends Influencing Long-Term Demand
Key players in the Rekovelle market are actively pursuing innovation, particularly through personalized ovarian stimulation, in order to address the growing need for more effective and safer fertility treatments. This approach customizes therapy—specifically drug dosage—based on individual patient factors such as body weight and anti-Müllerian hormone levels, rather than applying a uniform dose to all. In March 2023, Ferring Pharmaceuticals A/S, a Swiss pharmaceutical company, released findings from the PROFILE study, which stands as the first prospective, real-world investigation of Rekovelle (follitropin delta). The data indicated that approximately 74% of participants achieved retrieval of 4 to 19 oocytes, while ongoing pregnancy rates matched those recorded in earlier Phase 3 trials. An individualized dosing algorithm, accounting for body weight and AMH levels, was applied in 95% of instances. These outcomes therefore affirm the effectiveness and safety of Rekovelle when utilized in a real-world setting that emphasizes personalized ovarian stimulation.
Rekovelle Market Leading Companies Driving Competitive Growth
Major companies operating in the rekovelle market are Ferring Pharmaceuticals A/S
Access The Complete Rekovelle Market Report:
Rekovelle Market Largest Region: Which Geography Holds The Highest Market Share?
Europe was the largest region in the rekovelle market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rekovelle market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model